In a prospective observational study of 133 neutropenic episodes, interleukin (IL)-8 serum levels 12000 pg/mL at the onset of fever had a sensitivity of 53% and a specificity of 97% as a predictor of gram-negative bacteremia (GNB; positive predictive value, 73%; negative predictive value, 94%). The rates of early death differed significantly between patients with high and those with low IL-8 levels (3/11 vs.
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Prediction of Gram-Negative Bacteremia in Patients with Cancer and Febrile Neutropenia by Means of Interleukin-8 Levels in Serum:
Targeting Empirical Monotherapy versus Combination Therapy though several studies have suggested that the addition of an aminoglycoside may be beneficial for patients with GNB [2] [3] [4] . Early prediction of GNB would help to target those patients who are most likely to benefit from combination therapy and help to reduce the unnecessary toxicity and high cost associated with addition of an aminoglycoside to the treatment regimen.
Currently available laboratory techniques and clinical information are not sensitive or specific enough for the early detection of infectious causes of fever in patients with cancer who have neutropenia. Therefore, diverse markers of inflammation, such as levels of C-reactive protein or procalcitonin, have been evaluated as predictors of outcome or of different types of infection in febrile neutropenia. Previous studies have suggested that the level of IL-8, in particular, is a better predictor of GNB than are the levels of C-reactive protein and procalcitonin [5] [6] [7] . We undertook an observational study to assess the usefulness of a simple decision rule for choosing empirical combination therapy or monotherapy on the basis of the level of IL-8 in blood samples obtained at the onset of fever. An important finding was that knowledge of IL-8 levels not only allows safe initial monotherapy for patients with a predictably low risk of GNB but also appeared to help clinicians identify patients with a high risk of early death despite empirical combination therapy.
Patients and methods. Adult patients with cancer who have fever (temperature 138.0ЊC for 11 h) and neutropenia (!500 neutrophils/L) were enrolled. To define the infection, patients were physically examined and chest radiographs were obtained within 24 h of the onset of fever; a second radiograph was obtained for patients with persistent fever. At least 2 blood cultures were performed (15-20 mL of blood per culture), as were cultures of specimens of urine, sputum (if available), and suspicious lesions. Additional blood cultures were done during the study period if the patient's body temperature increased to recovered from the previous episode of febrile neutropenia and у7 days had elapsed without neutropenia and without fever. At the onset of fever and before the institution of empirical therapy, a venous blood sample was obtained. The sample was centrifuged within 1 h, and IL-8 serum levels were determined by use of an automated immunoluminescence analyzer (Immulite; DPC-Biermann) that can analyze a single sample in р40 min. The analyzer was available in the emergency clinical chemistry laboratory 24 h a day, 7 days a week. According to the manufacturer, the lower limit of detection of the assay is 2 pg/mL, and the upper limit of reference values (i.e., those for healthy individuals) measured in this laboratory was 18 pg/mL.
Cefepime was used as empirical therapy, either as a single agent (2 g every 8 h) or in combination with netilmicin (cefepime, 2 g every 8 h; netilmicin, 6-7.5 mg/kg of body weight once daily). Initial combination therapy was given to patients with IL-8 levels 12000 pg/mL, whereas all other patients received cefepime monotherapy. Therapy was modified as needed when microbiological findings became available. In patients with pulmonary infiltrates, early addition of amphotericin B was recommended.
An episode was defined as GNB if у1 blood culture of a specimen drawn at the onset of fever grew aerobic or facultative gram-negative rods, either with or without growing additional (gram-positive or anaerobic) bacteria. Sensitivities, specificities, and positive and negative predictive values were calculated along with 95% CIs. A modified APACHE III score (Acute Physiology and Chronic Health Evaluation version III; [8] ), including age and physiologic scoring for vital signs and laboratory tests, was calculated on the day of fever onset. This score, the highest temperature within 8 h after the onset of fever, and age were compared between patient subgroups by means of nonparametric 2-sided Mann-Whitney statistical tests. Differences in proportions were analyzed by means of Fisher's exact test.
We chose 2000 pg/mL as the cutoff concentration for IL-8 in serum on the basis of an analysis of data reported in previous studies [5] [6] [7] . We estimated that this value would predict GNB with a sensitivity of at least 40% and a specificity of at least 80%. We also assumed that the incidence of GNB would be 10% and the risk of death within 7 days would be 3%. Assuming an a level of 0.05 and a power ( ) of 0.90, we calculated 1 Ϫ b that 122 patients with IL-8 levels р2000 pg/mL had to be enrolled in the study to provide adequate discriminatory power and to confirm a low (р1%) risk of early death for patients treated with monotherapy.
Results. One hundred thirty-three episodes of febrile neutropenia in 98 patients (median age, 45 years; range, 17-80 years) were evaluable. Most patients had hematologic malignancies (acute leukemia, 48%; lymphoma, 24%). The median duration of neutropenia (!500 cells/L) per episode was 13 days (range, 3-179 days). The causes of neutropenic fever were as follows: unexplained, 30% of patients; nonpulmonary focal infection, 26%; pneumonia, 11%; and bacteremia, 36%. There were 15 episodes of GNB, including 4 cases of polymicrobial, mixed gram-negative/gram-positive bacteremia.
Median IL-8 levels varied greatly between different types of infection (table 1) ; the highest levels were measured in the subgroup of patients with GNB. There were 11 patients with IL-8 levels 12000 pg/mL; 8 of these 11 had GNB, corresponding to a sensitivity of 53% (95% CI, 27%-79%), a specificity of 97% (95% CI, 93%-99%), a positive predictive value of 73% (95% CI, 39%-94%), and a negative predictive value of 94% (95% CI, 88%-98%). Compared with the cutoff at 2000 pg/ mL, a cutoff at 1000 pg/mL would have improved the sensitivity from 53% to 60% (specificity, 94%; positive predictive value, 54%), and a cutoff at 500 pg/mL would have improved the sensitivity to 73% (specificity, 85%; positive predictive value, 38%).
In patients who were reenrolled in the study with a second episode of febrile neutropenia, the levels of IL-8 at onset of the episodes were similar only if the infections were of the same type ( , Spearman rank coefficient; ). IL-8 levels r p .64 P p .04 were not similar in those patients with different types of infections ( , Spearman rank coefficient; ). r p .31 P p .08 The all-cause mortality rate at 4 weeks after the onset of fever was 8% (11 of 133 patients). It was 27% (3 of 11) among patients with IL-8 levels 12000 pg/mL, compared with 7% (8 of 122) among patients with lower IL-8 levels (OR, 5.3; P p ). Four patients died from the presenting infection, all .049 within 1 week after presentation (table 2). Three of these 4 (2 with GNB that evolved into septic shock) had IL-8 levels 12000 pg/mL at the onset of fever; 1 patient with early death had an IL-8 level р2000 pg/mL (early death rate, 3/11 vs. 1/122; OR, 45.4; ). At the onset of fever, levels of IL-8 (and in-P p .002 fecting organisms) in these nonsurvivors were as follows: 17500 pg/mL (Escherichia coli and Staphylococcus epidermidis bacteremia), 3001 pg/mL (E. coli, Enterobacter species, and S. epidermidis bacteremia), 3016 pg/mL (pneumonia and septic shock, no organism), and 548 pg/mL (severe sepsis with acute abdomen, no organism).
As shown in table 2, the overall rate of response for monotherapy was 48% (59 of 122) among patients with IL-8 levels р2000 pg/mL, whereas the rate of response for combination therapy was 36% (4 of 11) among patients with higher IL-8 levels. Fourteen of the 15 gram-negative pathogens were susceptible to cefepime (and netilmicin). The exception was an Acinetobacter species with an MIC of 8 mg/mL for cefepime. The patient from which it was isolated had catheter-associated, mixed gram-negative/gram-positive bacteremia (IL-8 level, 632 pg/mL) and cefepime monotherapy reduced their fever, but the patient subsequently developed an acute necrotizing tracheobronchitis due to Aspergillus infection with dissemination.
In the subgroup of patients with GNB, there were no significant differences between patients with IL-8 levels 12000 pg/ mL and those with lower levels with respect to age (46 vs. 36 years, respectively), modified APACHE III score on the day of the onset of fever (31.5 vs. 32, respectively), or peak temperature within р8 h after the onset of fever (39.4ЊC vs. 38.9ЊC, respectively).
Discussion. Many previous cytokine studies have focused on distinguishing between documented or bacterial infection and unexplained fevers, or on the prediction of overall outcome. However, the therapeutic consequences of an early discrimination between documented infection and unexplained fevers appear to be limited. Gram-positive bacteremia in the neutropenic host is very often caused by coagulase-negative staphylococci but apparently do not need up-front empirical coverage, even when the isolates are resistant to oxacillin (i.e., resistant in vitro to the initially administered drug) [9, 10] . In contrast, the available data are much less conclusive concerning the optimal therapy for GNB, an infection that still carries a significant and hard-to-predict risk of evolution into septic shock and that may have a better outcome if treated with combination therapy [1] [2] [3] [4] .
Previous studies have provided limited data for estimating the sensitivity and specificity of IL-8 levels as predictors of GNB. Lehrnbecher and colleagues [7] calculated a sensitivity of 63% and a specificity of 99% with a cutoff value of 960 pg/mL, but grouped fungal infection and GNB together as the end point. Also, the number of GNB cases in their study was small ( ). In our experience with a protocol that obtained blood n p 5 samples from infected patients 3 times per week, the sensitivity and specificity to predict GNB at a cutoff level of 900 pg/mL were excellent but were limited because samples had been obtained р32 h after the onset of fever [5] .
Thus, the findings of the present study extend previous observations and clearly confirm that an IL-8 level in serum that is 12000 pg/mL at the onset of fever has a specificity and negative predictive value of 190% and a reasonable sensitivity of ∼50%-60%. Measurement of IL-8 serum levels at the onset of fever identified, within 1 or 2 h, patients with a very small likelihood of having GNB; that is, it identified them at a stage when clinical information was nonspecific and results of blood cultures were still unavailable. The high negative predictive value of IL-8 levels for GNB is reassuring, as is the virtual absence of acute mortality among the patients with lower IL-8 levels who received empirical monotherapy. Measurement of IL-8 levels allows unnecessary empirical therapy to be avoided. Cefepime monotherapy appears adequate for these patients; this finding corroborates the limited published data on the use of this drug for the treatment of neutropenic patients [11] [12] [13] . In the present study, response rates were low among patients with bacteremia due to organisms other than aerobic gramnegative rods and patients with pneumonia, which reflects the prevalence of bloodstream infections due to oxacillin-resistant staphylococci and of pulmonary infiltrates that are suggestive of invasive fungal pneumonia. It is unlikely that patients with these types of infection would benefit from initial therapy with a combination of a b-lactam and an aminoglycoside. Rather, it would be necessary to modify therapy to include a glycopeptide or an antifungal, respectively, to target these infections. It is important to stress that a low success rate was not associated with a high mortality rate.
The acute mortality rate was high among patients with IL-8 levels 12000 pg/mL. We believe that offering these patients initial empirical therapy with a combination of a b-lactam and an aminoglycoside remains justified, even though the benefit of such a strategy has not been proven formally and the high mortality rate in this subgroup of patients indicates a need for further, more aggressive therapy to improve outcomes. IL-8 measurement or similar tests will be useful for risk stratification if innovative therapeutic interventions targeting GNB and septic shock become available for clinical evaluation.
In conclusion, measurement of IL-8 levels in serum at the onset of fever in neutropenic patients may be a valuable tool to avoid the unnecessary administration of antimicrobials and the associated risks and cost for low-risk patients for whom empirical monotherapy is appropriate. In addition, the test used in the present study appeared to identify both early and rapidly those patients with high-risk GNB who need more aggressive therapy.
